Business
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies - -
About this update from Senti Biosciences Holdings, Inc.
[{"type":"text","content":"- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies - - Abstracts include new preclinical data demonstrating ongoing progress from collaboration with BlueRock Therapeutics and new technology development to enable Senti's future oncology pipeline products - SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held November 1-5, 2023, in San Diego, CA. Information about the poster sessions is as follows: NOT gate gene circuits expand the range of tumor-associated antigens addressable by CAR-NK and -T cell therapies In collaboration with GeneFab LLCAbstract number: 257 Location: Poster Halls A and B1Date and time: November 3, 2023, 9:00 am - 7:00 pm PT Small-molecule regulated safety switch for improved safety of CAR cell therapies in the brain In collaboration with BlueRock Therapeutics and GeneFab LLCAbstract number: 24 Location: Poster Halls A and B1Date and time: November 4, 2023, 9:00 am - 8:30 pm PT Smart sensor promoters drive state-specific gene circuits to convert immunosuppressive macrophages into an anti-tumor phenotype In collaboration with BlueRock Therapeutics and GeneFab LLCAbstract number: 430Location: Poster Halls A and B1Date and time: November 4, 2023, 9:00 am - 8:30 pm PT High-throughput discovery of constitutive promoters to drive strong expression of next-generation gene circuits in CAR-NK and -T cells Abstract number: 270 Location: Poster Halls A and B1Date and time: November 4, 2023, 9:00 am - 8:30 pm PT Following the presentations, copies of the poster presentations will be available on the Scientific Presentations & Publications section of the Senti Bio website. About Senti BioSenti Biosciences is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. The...